Synthetic Risk Transfers: BCBS Maps Capital-Relief Gaps

ByRegReportingDesk

On 17 February 2026 the Basel Committee on Banking Supervision published Synthetic risk transfers, a 31-page report on a market that has become an important source of capital relief for corporate credit risk. Across Canada, the euro area, the United Kingdom and the United States, the Committee estimates that about EUR 750 billion of assets are protected by synthetic risk transfers, roughly 1.1 percent of total bank assets in those four jurisdictions. For an average large or medium-sized European bank, the report finds that around 12 percent of the corporate loan book carries this kind of protection, and at some outlier banks the figure passes a third.

That scale is the reason the report exists. It sits inside the Committee’s continuing work on the interconnections between banks and non-bank financial intermediaries (NBFIs), and it is descriptive: an analysis of structures, market data and the supervisory approaches already in use across jurisdictions. No template changes because of it, and no capital requirement moves. For capital and reporting teams, the value is in what it signals about where supervisory attention is heading, especially significant risk transfer recognition and the thin disclosure around SRT financing.

Synthetic risk transfers let a bank cut the capital it holds against a loan portfolio while keeping the loans, and the borrower relationships, on its own balance sheet. Get the risk transfer recognition wrong, or lend to the very investor that bought the protection, and the capital relief a bank books can turn out smaller than the model assumed. Read the report as a preview of the questions supervisors are already putting to issuers.

Related reading: Pillar 3 Disclosure Requirements for Luxembourg Banks

A market stock-take from the Basel Committee

The report classifies itself in the BIS catalogue under the neutral “Others” series, and that label is accurate. It sets no standard, opens no consultation, and proposes no amendment to the Basel Framework. What it does is investigate three things: the range of SRT structures and the risks they carry, the size and participants of the market, and the approaches supervisors take across jurisdictions.

The distinction matters for how you file it internally. A monitoring report of this kind feeds supervisory thinking and future policy work; it does not reset a reporting obligation the way an implementing technical standard does.

One terminology trap is worth clearing early, because it affects which population you map the report to. The report uses SRT to mean synthetic risk transfer, and it flags in its own footnotes that synthetic risk transfer is a subset of a broader category, significant risk transfer, a term used in the euro area and the United Kingdom for any transaction that produces capital relief, whether through a traditional cash securitisation or a synthetic one. Not every significant risk transfer is synthetic. If your teams already track a significant-risk-transfer pipeline, the report speaks to the synthetic slice of it, not the whole.

The synthetic risk transfer market in numbers

The headline figures are the part of the report most likely to be quoted back at you, so it helps to know exactly what each one measures.

  • Assets protected by SRTs sit between 0.9 percent and 1.8 percent of the consolidated total assets of banks in individual jurisdictions, with an average of about 1.1 percent.
  • The total value of protected assets in Canada, the euro area, the United Kingdom and the United States is estimated at about EUR 750 billion, again around 1.1 percent of total bank assets.
  • Corporate loans are the largest asset class protected. About 12 percent of the corporate book of an average large and medium-sized European bank benefits from SRT protection, with wide dispersion around that figure.
  • Large banks dominate issuance, though the report notes smaller banks have recently become more active.

The denominator is what stops these numbers from being misread. The 1.1 percent measures against total bank assets, not risk-weighted assets or the capital base, so it understates how concentrated the effect is inside the corporate book. The 12 percent corporate-book figure is where the capital relief actually bites, and the dispersion behind the average is the point: a bank protecting a third of its corporate exposures is running a very different profile from one sitting near the mean. On the investor side, the protection is bought mostly by private investment funds such as credit funds and hedge funds, alongside pension funds and insurers, with public sector entities playing a material role in some markets.

How capital relief is recognised, and where it stops

The mechanism underneath all of this is the Basel Framework’s securitisation chapter. Traditional and synthetic securitisations are defined in chapter CRE40, and a synthetic structure has to feature at least two tranches that reflect different degrees of credit risk in the underlying pool. The operational requirements for recognising a synthetic securitisation for capital purposes sit at CRE40.25 and the paragraphs that follow: compliance of the credit risk mitigant, collateral and guarantor eligibility, limits on terms and conditions that would cut the amount of risk transferred, a legal opinion on enforceability, and rules on clean-up calls.

On top of that Basel baseline, jurisdictions set their own quantitative bar for how much risk must move. The report lays the main ones side by side. CRE40.25 requires significant credit risk to be transferred; the 50 percent and 80 percent quantitative tests are set at the jurisdictional level, with the EU specifying its tests in Article 245(2) CRR. In the EU, Article 245(2) CRR deems significant risk transferred where, for transactions with mezzanine positions, the risk-weighted exposure amounts of mezzanine positions retained by the originator do not exceed 50 percent of all mezzanine positions; where there are no mezzanine positions, the originator must retain no more than 20 percent of the exposure value of the first-loss tranche and that tranche must exceed expected loss by a substantial margin. The current UK framework applies equivalent retained-position tests through the PRA regime. The EU legal anchor for this is Article 245 of the Capital Requirements Regulation. For portfolios of Standardised Approach exposures, the PRA expects firms to compare the detachment point of the tranches sold or protected with KSA. It treats 1.5 × KSA as a prudent fallback and may accept a lower scalar where the firm can evidence that this is appropriate for the transaction. Canada requires an RWA reduction of at least 60 percent for internal ratings-based pools, including an expected-loss adjustment. The United States sets no fixed quantum, and US banks typically protect the first 12.5 percent of losses to maximise the reduction on the retained senior tranche under the US capital rule.

Here is the part reporting teams most often underestimate. Clearing the quantitative threshold does not settle the question. The report is explicit that supervisors reserve the right to review and challenge the eligibility of capital relief throughout the life of a transaction, and that they can object where the relief is not justified by a commensurate transfer of credit risk even when the numeric criteria are met. The tools they name are a higher risk weight on the transaction, a Pillar 2 add-on, restrictions on further SRT use, or refusing to recognise the transfer at all. Whatever capital relief is recognised affects securitisation RWA and, in turn, own-funds requirements. In EU COREP, securitisation positions and their own-funds requirements are reported in template C 13.01, with transaction-level detail in C 14.00 and C 14.01; there is no standalone SRT ‘capital saving’ field in an own-funds template. Our guide to COREP own funds reporting sets out where those securitisation RWA lines live.

Approval choreography differs by jurisdiction and is easy to get wrong for cross-border books. The ECB offers regular and fast-track SRT notification processes. Under the regular process, originators should notify their intention at least three months before expected closing. The fast-track has applied since January 2026 to eligible simpler and more standardised SRTs; institutions should signal their intention and submit the fast-track notification within the shorter timelines the ECB specifies for eligible transactions. The PRA does not operate a pre-approval process; a firm relying on the deemed transfer of significant credit risk must notify the PRA no later than one month after the date of transfer, while SS9/13 expects early discussion for material or complex transactions. In the United States and Canada, ordinary qualifying structures generally do not require transaction pre-approval or notification. In the United States, however, a Board-regulated institution using directly issued credit-linked notes may need Federal Reserve reservation-of-authority approval to obtain the intended synthetic-securitisation capital treatment. Canada’s OSFI proposed SRT notification and reporting requirements for CAR 2027 in its November 2025 consultation.

SRT financing, the gap supervisors keep naming

If the report has a centre of gravity, it is here. Some SRT investors boost returns by borrowing against their positions in the repo market. The BCBS report notes that the financing bank is usually different from the SRT originating bank; supervisors are not aware of banks financing their own originated SRTs, though a recent survey reported that one bank may be doing so, and data on the scale of SRT financing remain scarce. When a bank both buys protection from an investor and lends that investor the money to post as collateral, part of the credit risk it thought it had shed stays inside the banking system, funded by debt the bank itself extended.

The report is candid that supervisors are early in understanding this. Data on the scale of SRT financing are not available, current Pillar 1 rules carry few explicit limits on it, and some supervisors have flagged concerns about insufficiently prudent practices. The public statements it cites are worth keeping on file: the UK PRA set out its concerns in a Dear CFO letter in April 2025 aimed at illiquid and structured financing portfolios with a specific focus on SRT financing; the ECB warned in a February 2025 supervisory newsletter that such financing can leave hidden risk in the banking system with lower capital coverage overall; the EBA picked up the theme in its June 2025 risk assessment report; and the IMF pointed to leverage in SRTs in its October 2024 Global Financial Stability Report and a 2025 working paper, citing evidence of banks lending to credit funds to buy notes issued by other banks. My reading is that this section, not the market-size chapter, is what the report was written to set up.

The capital arithmetic explains why direct exposure is rare and why financing is the route of concern. A first-loss SRT note held outright would attract a 1250 percent risk weight, which makes holding one directly uneconomic. Financing an investor against an SRT note creates a different bank exposure. The report warns that, especially where the financing sits in the trading book, capital calibrated on the assumption that the collateral can be liquidated may not adequately capture the liquidation risk of an illiquid SRT note.

What Pillar 3 already shows, and what it leaves out

The topic that brings most reporting officers to this report is disclosure, so it is worth being precise about what already exists. Banks are expected to disclose qualitative and quantitative information on their securitisation exposures through Pillar 3, and the level of detail varies by jurisdiction. In the EU, Article 7 of Regulation (EU) 2017/2402 requires originators, sponsors and SSPEs to make prescribed transaction documentation and quarterly underlying-exposure information available to specified recipients. In the UK, for PRA-authorised firms the current transparency obligations arise under Article 7 of the PRA Rulebook Securitisation Part, rather than directly from Regulation (EU) 2017/2402.

The gap the report identifies is specificity. EU Pillar 3 is more granular than an aggregate securitisation-RWA figure. Under Implementing Regulation (EU) 2024/3172, template EU-SEC1 contains separate synthetic and ‘of which SRT’ columns with asset-class rows, while EU-SEC3 identifies synthetic transactions and reports risk-weighted exposure amounts and capital charges. These disclosures still do not provide a transaction-by-transaction measure of capital saved relative to the portfolio’s pre-SRT capital requirement. In the United States, Regulation Q requires in-scope Board-regulated institutions to disclose securitisation information that expressly includes synthetic securitisations and quantitative traditional/synthetic categorisation. In Canada, OSFI’s 2026 BCAR instructions cover securitisation exposures; the November 2025 CAR 2027 consultation proposes explicit SRT notification and reporting requirements. Neither regime provides a transaction-by-transaction pre-SRT versus post-SRT capital-saving measure. So a reader of public Pillar 3 cannot isolate how much capital a bank has saved through synthetic risk transfers, and the report states plainly that disclosure of SRT activities and their impact on bank capital remains limited. That is an observation about the current framework, not a proposal for a new SRT return. Anyone treating the report as the trigger for a fresh disclosure template is reading ahead of the text.

The same transparency question runs through adjacent Pillar 3 workstreams, including the shadow-banking and equity exposure lines covered in our note on the CRR3 Pillar 3 disclosure package. The BCBS report nevertheless concludes that public information on SRT activity remains insufficiently granular to provide a clear picture of its effect on banks’ risk profiles.

The risks the report puts on supervisors’ radar

Section 5 sets out why the Committee thinks the market merits continued monitoring even though it judges current SRT structures simpler and better scrutinised than the credit risk transfers that fed the 2008 crisis. A bank that leans heavily on SRTs makes its lending capacity dependent on the willingness and ability of NBFI protection providers to keep taking credit risk. In a downturn those providers may pull back exactly when losses rise, which can make credit supply more procyclical, and reliance on unfunded SRTs or on short-term financing from NBFIs can sharpen that effect.

Banks manage this by spacing out SRT maturities, matching the maturity of protection to the underlying loans, diversifying protection providers, and limiting unfunded structures. The report’s caution is that these mitigants have not been tested by large-scale credit losses and that SRT markets stay opaque to regulators and participants alike. Two structural risks get particular attention. Resecuritisation of SRTs is prohibited in the European Union outside certain legitimate purposes and attracts a more conservative treatment through a higher supervisory p-factor where it occurs. Step-in risk, the risk that a bank supports a stressed vehicle it has no contractual obligation to support, is one the report expects banks to identify and manage for securitisation vehicles specifically, consistent with the Committee’s 2017 step-in risk guidelines. The systemic edge of all this connects to the macroprudential toolkit, which our explainer on macroprudential buffer stacking works through.

The metrics behind the next supervisory conversation

The most useful pages for a reporting or capital function are the ones that show the metrics supervisors have used or could use to monitor a bank’s dependence on SRTs. The report names them directly: the overall capital relief obtained, the share of assets and specific portfolios protected by SRTs relative to the relevant totals, the cost of the protection purchased, and the maturities of outstanding transactions along with any maturity mismatch against the underlying assets.

Two operational details attach to those metrics. For synthetic securitisations, where the hedged exposures have different maturities the longest maturity is used. A maturity mismatch arises when the maturity of the credit protection is shorter than the maturity of the underlying exposure, and the Basel maturity-mismatch treatment then applies; where the residual maturity of the protection falls below five years, the bank must hold additional capital for the mismatch. That gives banks an incentive to remove loans whose maturities run beyond the protection, purely to preserve the intended relief. On cost, the report records a supervisory expectation to scrutinise high-cost credit protection and to weigh the cost of protection when assessing a bank’s capital adequacy, so an expensive hedge does not automatically translate into clean relief. These are the levers a supervisor can already pull, which is why the report reads less like background and more like a checklist a bank can expect to be measured against.

Frequently Asked Questions

Does the February 2026 report change any Basel capital requirement or add a new reporting template?

No. It is an analytical monitoring report in the BIS “Others” series. It describes existing Basel Framework requirements and jurisdictional practice, and it sets no new standard, consultation, deadline, or return. Any capital treatment or disclosure obligation you apply today continues to come from the Basel Framework, the CRR and its technical standards, and your national supervisor. This report changes none of that.

What is the difference between a synthetic risk transfer and a significant risk transfer?

The report uses synthetic risk transfer for a transaction that moves credit risk to a counterparty while the bank keeps the assets on balance sheet. Significant risk transfer is the broader term used in the euro area and the United Kingdom for any transaction that produces capital relief, whether through a traditional cash securitisation or a synthetic one. Every synthetic risk transfer that achieves recognition is a significant risk transfer, but a cash securitisation can be a significant risk transfer without being synthetic.

Why does the loan stay on the balance sheet if the risk has been transferred?

In a traditional securitisation the bank sells the assets to a special purpose entity. In a synthetic securitisation the bank keeps ownership of the loans and transfers only the credit risk, through a credit default swap, a guarantee, or credit-linked notes. That structure is what lets a bank protect a portfolio while preserving the customer relationship, and it is why the exposures still appear on the bank’s books even after protection is recognised.

Are unfunded SRTs treated differently from funded ones?

Most SRTs are fully funded, meaning the investor posts high-quality collateral upfront for the full protected amount so the bank carries little counterparty risk. With an unfunded SRT the bank holds capital against the risk that the protection provider defaults, and that capital depends on the provider’s credit quality. The report treats heavy reliance on unfunded protection and on NBFI providers as a source of additional stress, because the value of the protection then tracks the health of the provider.

How are currency and maturity mismatches handled in the capital calculation?

Where eligible credit protection is denominated in a different currency from the exposure, CRE22.82 reduces the amount deemed protected by applying the prescribed currency-mismatch haircut. For synthetic securitisations with underlying exposures of different maturities, the longest maturity is used; where protection matures before the underlying exposure, the maturity-mismatch treatment in CRE22.10 to CRE22.14 applies. Early termination features can shorten that protection maturity further, which is why they are scrutinised.

Can a bank resecuritise its SRTs?

In the European Union resecuritisation is prohibited except for certain legitimate purposes, and where it is permitted it carries a more conservative capital treatment through a higher supervisory p-factor. The report notes it has not identified instances of SRT resecuritisation, and treats the prospect as a transparency and modelling risk rather than a current practice.

Does the ECB pre-approve an SRT before it closes?

The ECB operates regular and fast-track SRT notification processes. The regular process calls for notice at least three months before expected closing; the fast-track has applied since January 2026 to eligible transactions and uses shorter notification and assessment timelines. Informal dialogue with the ECB does not constitute explicit or implicit approval of significant risk transfer. Even after closing, supervisors in the EU can object to the recognition of capital relief where it is not matched by a commensurate transfer of credit risk, so a notified transaction is not a guaranteed one.

Key Takeaways

  • The BCBS published Synthetic risk transfers on 17 February 2026 as a monitoring and analysis report; it changes no capital rule and adds no reporting return.
  • About EUR 750 billion of assets are protected by SRTs across Canada, the euro area, the UK and the US, roughly 1.1 percent of total bank assets, and around 12 percent of the corporate book at an average large or medium European bank.
  • CRE40.25 requires significant credit risk transfer; jurisdictions set their own quantitative tests, with the EU specifying its tests in Article 245(2) CRR. Under the EU Article 245 deemed-transfer tests, retained mezzanine RWEA must not exceed 50 percent of all mezzanine-position RWEA; where there is no mezzanine position, the originator must retain no more than 20 percent of the exposure value of a qualifying first-loss tranche.
  • Clearing the quantitative threshold does not guarantee relief: supervisors can impose a higher risk weight, a Pillar 2 add-on, or refuse recognition where the transfer is not commensurate with the risk moved.
  • Notification processes differ: the ECB’s regular process calls for notice at least three months before closing, while its fast-track has applied to eligible SRTs since January 2026; in the UK, a firm relying on the deemed-transfer test must notify the PRA no later than one month after the date of transfer.
  • SRT financing is the flagged blind spot: data are scarce, Pillar 1 limits are few, and a first-loss SRT note held directly would attract a 1250 percent risk weight, which pushes exposure into the financing route; the BCBS report notes the financing bank is usually different from the originating bank.
  • EU Pillar 3 includes SRT-specific information: EU-SEC1 separately identifies synthetic exposures and ‘of which SRT’ amounts by asset class, while EU-SEC3 reports risk-weighted exposure amounts and capital charges for synthetic transactions. It does not, however, disclose a transaction-by-transaction pre- versus post-SRT capital saving.
  • Expect supervisory questions built on the report’s own metrics: overall capital relief, share of portfolios protected, cost of protection, and transaction maturities, including cases where the protection matures before the underlying exposures.

Sources and References

Where the SRT file goes from here

Nothing in the February 2026 report needs a change to a return this quarter. What it needs is a bank that can answer the report’s own questions about its synthetic risk transfer book before a supervisor asks them: how much capital relief the transactions deliver, what share of the corporate portfolio they cover, how the protection maturities line up against the loans, and whether any financing extended to protection buyers has quietly pulled risk back onto the balance sheet. My reading is that the disclosure gap the Committee names, more than the headline market-size numbers, is where the next policy step will come from, so the practical move now is to make the SRT figures behind your COREP own funds returns and your Pillar 3 securitisation lines defensible on their own terms.

Disclaimer: The information on RegReportingDesk.com is for educational and informational purposes only. It does not constitute legal, regulatory, tax, or compliance advice. Always consult your compliance officer, legal counsel, or the relevant supervisory authority for guidance specific to your institution.

Similar Posts